Stručni rad

Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma

Smiljka Popović-Suić
Borna Šarićić

Sažetak

The aim of this study was to evaluate early treatment response following intravitreal bevacizumab therapy in 4 patients with neovascular glaucoma. Four patients with neovascular glaucoma and pronounced congestion of anterior chamber received intravitreal bevacizumab injection (1.25 mg/0.05 mL). Intravitreal bevacizumab resulted in marked regression of anterior segment neovascularization documented by fluorescein angiography and iridography, and relief of symptoms within 24 hours. Cyclocryocoagulation was carried out only if pressure was insufficiently controlled by topical therapy. Follow up examination was performed at 1 month. In conclusion, intravitreal bevacizumab leads to rapid regression of iris and angle neovacularization in the early period of observation. Controlled randomized trial is needed to test whether intraocular injections of bevacizumab provide long term benefit to patients with neovascular glaucoma.

Ključne riječi

Neovascular glaucoma; Bevacizumab

Hrčak ID:

22769

URI

https://hrcak.srce.hr/22769

Datum izdavanja:

1.4.2008.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.639 *